Ascentage Pharma Group International (AAPG) Non-Current Deferred Tax Liability (2022 - 2024)

Historic Non-Current Deferred Tax Liability for Ascentage Pharma Group International (AAPG) over the last 3 years, with Q4 2024 value amounting to $1.7 million.

  • Ascentage Pharma Group International's Non-Current Deferred Tax Liability fell 2413.51% to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.7 million, marking a year-over-year decrease of 2413.51%. This contributed to the annual value of $1.7 million for FY2024, which is 8431.13% down from last year.
  • Ascentage Pharma Group International's Non-Current Deferred Tax Liability amounted to $1.7 million in Q4 2024, which was down 2413.51% from $2.2 million recorded in Q4 2023.
  • Ascentage Pharma Group International's Non-Current Deferred Tax Liability's 5-year high stood at $2.5 million during Q4 2022, with a 5-year trough of $1.7 million in Q4 2024.
  • For the 3-year period, Ascentage Pharma Group International's Non-Current Deferred Tax Liability averaged around $2.1 million, with its median value being $2.2 million (2023).
  • Per our database at Business Quant, Ascentage Pharma Group International's Non-Current Deferred Tax Liability plummeted by 979.4% in 2023 and then crashed by 2413.51% in 2024.
  • Over the past 3 years, Ascentage Pharma Group International's Non-Current Deferred Tax Liability (Quarter) stood at $2.5 million in 2022, then fell by 9.79% to $2.2 million in 2023, then fell by 24.14% to $1.7 million in 2024.
  • Its Non-Current Deferred Tax Liability stands at $1.7 million for Q4 2024, versus $2.2 million for Q4 2023 and $2.5 million for Q4 2022.